Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138705 | 1.00 | CA1 (0.36) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL26889942 | 0.84 | CA1 (0.42) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL26890013 | 0.84 | CA1 (0.42) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL26889902 | 0.84 | CA1 (0.42) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL26889939 | 0.84 | CA1 (0.42) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL25125498 | 0.84 | CA1 (0.42) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL26893755 | 0.83 | CA1 (0.36) | CA1CA2CA4HRH3CYP2D6 | |
| SCHEMBL21146195 | 0.83 | CA1 (0.36) | CA1CA2CA4HRH3CYP2D6 | |
| SCHEMBL26704494 | 0.83 | CA1 (0.36) | CA1CA2CA4HRH3CYP2D6 | |
| SCHEMBL26704498 | 0.83 | CA1 (0.36) | CA1CA2CA4HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107763-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CA1 2831/4885CA2 2245/4885CA4 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.